Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118652 | 0.90 | FFAR1 (0.40) | FFAR1EGLN1FFAR4ACACBEGLN3 | |
| SCHEMBL20118720 | 0.87 | FFAR1 (0.37) | FFAR1EGLN1ACACBEGLN3 | |
| SCHEMBL20118731 | 0.81 | HSD17B1 (0.38) | RARBFFAR1EGLN1ACACBEGLN3 | |
| SCHEMBL10325691 | 0.81 | PLAU (0.40) | RARBPLAUFFAR1MTNR1AMTNR1B | |
| SCHEMBL19258694 | 0.78 | FFAR1 (0.33) | FFAR1EGLN1FFAR4ACACBEGLN3 | |
| SCHEMBL18622100 | 0.78 | FFAR1 (0.33) | FFAR1EGLN1FFAR4ACACBEGLN3 | |
| SCHEMBL25573555 | 0.78 | FFAR1 (0.41) | RARBFFAR1FFAR4 | |
| SCHEMBL20118719 | 0.73 | CYP2A6 (0.54) | CYP2A6 | |
| SCHEMBL20118724 | 0.72 | FFAR1 (0.35) | FFAR1ACACB | |
| SCHEMBL17954457 | 0.72 | FFAR1 (0.44) | RARBFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667840-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| US-11667840-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| EP-3529331-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-10-07 | — | — | EP | disclosed |
| US-20190330530-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| WO-2018077765-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667840-B2 | Liquid-crystalline medium | FES, BLM, CXCL12 | RARB 2395/4885PLAU 2460/4885ASIC3 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.